We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
20/1/2021 22:08 | Hope they go up for new investors from here but so many and you've been burned I guess. Good luck but I'd rather take the loss and look somewhere like EVG to make those bad losses back as can't see GDR ever getting back to my cost let alone a profit | peanut100 | |
20/1/2021 21:51 | No disrespect but I feel you should suggest others on GDR thread buy EVG not us GDR. I had them and took a huge loss and won't look back at that woeful company and CEO. GDR holders may get their losses back here. How can you have a testing kit in Covid times and not sell one unit. Boat and missed springs to mind. They Raised money at huge discount when price went up. EVG holders be aware of this as thats what the broker does for fees. | peanut100 | |
20/1/2021 19:40 | Rb. Well spotted. Amateur hour. | bumpa33 | |
20/1/2021 19:38 | U should all take a punt on GDR !Risk/reward is massively to upside.Thank me later. | amaretto1 | |
20/1/2021 16:00 | Marex are a new mm, they’re making markets in all the retail stuff. They’re ex Cantors. And no, it doesn’t mean a placing 🤦🏼 | bumpa33 | |
20/1/2021 14:25 | At some point the herd will arrive and the rise will be rapid. However, I have absolutely no clue when that will happen as it should have occurred already..... | nobbygnome | |
20/1/2021 13:49 | Well done those who added more today. I was ready to nibble a few more if we had hit 9.5, so did not get my target price. I have no feel for this company's share price direction whatsoever, but if this turns out to be another false rise, I have some funds aside. A bit top heavy now though, so would rather not have the chance! | lovewinshatelosses | |
20/1/2021 13:05 | Broccoli . . . a breath of fresh air The importance of eating our greens is impressed on us from an early age. Now a small drug developer on Aim reckons that the humble broccoli may help to stave off some of the breathing problems brought on by Covid-19 and pneumonia. The Cheshire-based Evgen Pharma is part-way through a mid-stage study of its SFX-01 drug, the active ingredient in which is a synthetic of a compound called sulforaphane, which is found in vegetables such as broccoli, cabbage and kale. A compound in broccoli is a key ingredient in Evgen Pharma’s SFX-01 GETTY IMAGES For more than a decade Evgen has been developing the drug as a possible treatment for late-stage breast cancer but bosses think it can be reworked to reduce the severity of acute respiratory distress syndrome in pneumonia and Covid-19 patients. Scientists believe that SFX-01 can boost the Nrf2 pathway, part of the body’s natural defence against inflammation brought on by viral infections. So far Evgen has recruited 56 patients to the trial, with the goal to find another 250 or so more people to test the drug on. Data from the first 100 patients is expected to start coming out about April and the study is set to finish later in the year. The shares closed down ½p, or 3.9 per cent, at 9¾p. | toffeeman | |
20/1/2021 12:49 | No chance toffee - making markets in new small caps and AIM. No reason to raise cash for the minute. | peanut100 | |
20/1/2021 12:38 | >>toffee Yes, that has been mentioned elsewhere. However people often walk on cracks in the pavement without realising that they may fall in to an abyss. They have been warned. | longshanks | |
20/1/2021 12:08 | U still in VAL ?Disappointing share price action there.Been buying here today | amaretto1 | |
20/1/2021 10:55 | Any more info on what the Times said about EVG? | on target | |
20/1/2021 10:54 | A company getting a new broker can potentially mean that Toffeeman - maybe that's what you were thinking of? | on target | |
20/1/2021 10:51 | SNG are also one of the companies where they have just started making a market. Pretty sure there isn't a fund raising coming there.....😜 | nobbygnome | |
20/1/2021 10:49 | >> toffee MARX are a new outfit who have recently started creating a market in a whole series of shares. It most definitely does not mean that necessarily... | nobbygnome | |
20/1/2021 10:47 | They have enough cash until end of year according to the CEO's interview last month and their business model is to seek non-dilutive funding to advance the pipeline, and so any near term fund raise would be unlikely imho, unless for a very special material event. Gl :-) | moneymunch | |
20/1/2021 10:39 | MREX, I see 6 on the bid. Looking strong here today. | albert arthur | |
20/1/2021 10:39 | Didn't someone comment elsewhere that the arrival of a new MM is indicative of a possible placing? | toffeeman | |
20/1/2021 10:26 | MARX (the new MM) is now on the bid! | nobbygnome | |
20/1/2021 10:22 | On and UP!!! Gla ..U2 Ng. ;-) | moneymunch | |
20/1/2021 10:18 | Well I would be more than happy to if he stopped making ridiculous over optimistic predictions about company and trial events. As I keep on saying that is ultimately counter productive. Timbo and I know about recruitment to trials and both of us are impressed by the 56 recruited so far. Yet the price went down..... | nobbygnome | |
20/1/2021 10:12 | Seemed like a tiny tree shake yesterday pm... on the back of solid news!! | bocker01 | |
20/1/2021 10:11 | Yep a formidable duo! | bocker01 | |
20/1/2021 10:11 | You need to team up with Money, Nobby. Boundless energy pulling in the right direction! | bocker01 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions